Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
复制标题
DOI：
10.1016/j.soc.2015.03.008
复制
发表时间：
2015-07-01
影响因子：
1.9
通讯作者：
Lee, Nancy
中科院分区：
文献类型：
--
作者：
Kamran, Sophia C.;Riaz, Nadeem;Lee, Nancy
鼻咽癌在美国并不常见，每10万人中只有0.2至0.5例；这与中国南部和香港的发病率形成了鲜明对比，后者的发病率为每10万人中有25至50例。EB病毒与鼻咽癌的发生有潜在的联系。在美国、丹麦和香港，单纯的放射治疗作为一种单一治疗方式导致了相似的10年存活率(分别为34%、37%和43%)。多项研究表明，同步放化疗在治疗晚期疾病中具有优势。放射治疗仍然是抢救治疗的支柱，现代技术使临床医生能够在没有过度毒性的情况下实现充分的局部控制。
Nasopharyngeal carcinoma is uncommon in the United States, with only 0.2 to 0.5 cases per 100,00 people; this is in contrast to southern China and Hong Kong, where the incidence is 25 to 50 per 100,000 people. There is a potential link between Epstein-Barr virus and the development of nasopharyngeal carcinoma. Radiotherapy alone as a single modality leads to similar 10-year survival rates in United States, Denmark, and Hong Kong (34%, 37%, and 43%, respectively). Multiple studies have shown an advantage to concurrent chemoradiation in the treatment of advanced disease. Radiation therapy remains the mainstay of salvage therapy, and modern techniques have allowed clinicians to achieve adequate local control without excessive toxicity.